BPC-157 Stable

Overview

Acetate salt form providing better stability and shelf life.

Reported benefits

Same as BPC-157 with enhanced stability

Protocols & dosing

Typical dosage: 250-500 mcg (daily).

Detailed dosing protocols have not yet been catalogued.

FDA & legal status

BPC-157 Stable is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed BPC-157 Stable from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place BPC-157 Stable on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 (Do Not Compound list) effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026 (White Oak Campus, Silver Spring, MD). PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. If PCAC votes favorably, moves to 503A Bulks List. NOT currently on 503A Bulks List — compounding still requires physician Rx and pharma-grade API. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

Vendor information

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Side effects & safety

Reported side effects: Minimal, same as regular BPC-157

References

No external sources have been catalogued for this article yet.